Interpace Diagnostics PanDNA

Interpace Diagnostics has launched PanDNA, a new product that stratifies patients' risk of developing pancreatic cancer based on specific molecular criteria. PanDNA assigns risk for a cyst based on an accumulation of three molecular criteria: DNA quantity, an oncogene panel, and a tumor suppressor gene panel. If the product has a higher number of findings, it is an indication of a potentially higher risk of prognosis, the company said. The product is currently in the initial phase of launch, but Interpace said that it expects the final rollout to come on or around Oct. 15.